# Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
Canonical URL: https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-bofa-securities-2026-health-care-conference
Ticker: CRBU
Company: Caribou
Source: Caribou
Published: 2026-05-05 20:05 EST
Original Source URL: https://investor.cariboubio.com
## Summary

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at BofA

## Article Body
BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at BofA
## Recent Company News
- 2026-05-27 20:05 EST — [Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Caribou
- 2026-05-13 20:05 EST — [Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Caribou
- 2026-05-12 13:30 EST — [Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-highlight-vispa-cel-and-cb-011-programs-during-oral-presentations-at-the-2026-european-hematology-association-eha-annual-meeting) — Source: Caribou
- 2026-05-07 20:06 EST — [Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Caribou
- 2026-05-05 20:05 EST — [Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-bofa-securities-2026-health-care-conference) — Source: Caribou
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)